Topical resiniferatoxin for the treatment of vestibulodynia: a prospective observational trial Authors: Filippo Murina, Cecilia Fochesato, Matteo Mantovani, Matilde Slanzi, Marianna Donini, Nicla Toni, Valeria Savasi Published: 2026 ABSTRACT AbstractBackgroundVestibulodynia is the most common subtype of vulvodynia and is characterized by persitent, contact-evoked pain localized to the vulvar vestibule. Increasing evidence supports a neuropathic pain mechanism in vestibulodynia, including vestibular hyperinnervation, neuroinflammation, and overexpression of the transient receptor potential vanilloid 1 receptor. Despite this, there are no standardized treatment protocols, and available therapies often provide incomplete relief or are limited by systemic side effects. Targeted topical therapies may offer advantages by acting directly on peripheral pain generators. Resiniferatoxin, a highly potent transient receptor potential vanilloid 1 receptor agonist, induces long-lasting desensitization of nociceptive fibers and may represent a novel therapeutic option for vestibulodynia.ObjectiveTo evaluate the clinical efficacy, tolerability, and neurophysiological effects of topical resiniferatoxin cream applied to the vulvar vestibule in women with vestibulodynia.Study DesignThis was a prospective, observational pilot study. Premenopausal women aged ≥18 years with a diagnosis of vestibulodynia lasting at least 3 months were enrolled. Participants applied topical resiniferatoxin 10 mcg/mL cream to the vulvar vestibule once daily for 4 weeks using a standardized dosing dispenser. Outcomes included patient-reported pain intensity (visual analog scale for pain and dyspareunia), vestibular cotton swab test scores, levator ani muscle tone, and vestibular current perception thresholds at 2000, 250, and 5 Hz. Baseline and 1-month follow-up values were compared using the Wilcoxon signed-rank test and McNemar test, as appropriate.ResultsTwenty-four women were enrolled (median age 31 years; median vestibulodynia duration 66 months). Most participants reported a transient, tolerable burning sensation after resiniferatoxin application; 5 women (20.8%) discontinued treatment due to local discomfort. Among participants with complete follow-up, significant improvements were observed at 1 month in provoked vulvar pain and dyspareunia, with median Visual Analog Scale reductions of 2.0 (P=.01) and 2.5 (P=.01) points, respectively. Vestibular cotton swab test scores also improved. current perception thresholds values increased significantly at 250 Hz and 5 Hz, indicating reduced sensitivity of Aδ and C fibers, while no significant change was observed at 2000 Hz. A reduction in levator ani hypertonicity was observed but did not reach statistical significance.ConclusionTopical resiniferatoxin was associated with meaningful reductions in vulvar pain and dyspareunia and with objective improvements in vestibular nerve fiber sensitivity in women with vestibulodynia. These findings support the role of transient receptor potential vanilloid 1 receptor-mediated peripheral mechanisms in vestibulodynia and suggest that resiniferatoxin may be a promising targeted therapy. Larger, placebo-controlled trials with longer follow-up are warranted to confirm these preliminary results.Key words: capsaicin, dyspareunia, neuropathic pain, resiniferatoxin, vulvar pain, vulvodyinia AJOG Global Reports at a Glance Why was this study conducted? To evaluate the clinical effectiveness and tolerability of topical resiniferatoxin, a potent vanilloid receptor VR1 (TRPV1) agonist, as a targeted treatment for vestibulodynia, a localized neuropathic pain condition with limited evidence-based topical therapies. Key findings Four weeks of daily topical resiniferatoxin application significantly reduced provoked vulvar pain and dyspareunia and increased vestibular pain thresholds at Aδ and C fiber frequencies, with overall good tolerability and limited treatment discontinuation. What does this study add to what is known? This study provides the first prospective clinical data on topical resiniferatoxin treatment in women with vestibulodynia and is among the first to associate symptom improvement with objective neurophysiological measures, supporting TRPV1-targeted topical therapy as a promising approach for localized neuropathic vulvar pain. Introduction Vestibulodynia (VBD) is characterized by vulvar discomfort elicited by contact with the vulvar vestibular region, persisting for 3 months or longer, without identifiable etiologies of vulvar pathology.1 VBD is the most common subtype of vulvodynia, representing about 80% of cases. It is characterized by pain localized to the vestibule, which is often provoked by mechanical stimuli such as touch, friction, stimulation, or attempted penetration during sexual intercourse (dyspareunia).2 Individuals experiencing vulvar pain exhibit diminished quality of life, frequently accompanied by depressive and anxiety disorders.3 Patients often perceive themselves as isolated, disregarded, or subjected to mistreatment by the medical establishment, which fails to acknowledge their experiences seriously. The pathophysiology of VBD encompasses microbiological, immunological, hormonal, genetic, and psychological aspects.4 Neuroinflammation and allodynia, where typically nonpainful stimuli such as light touch or mild warmth induce pain, elucidate the symptoms and indications of vestibular disorders.4 Current studies indicate heightened density of nerve fibers exhibiting hyperinnervation in the vestibular mucosa of individuals with VBD relative to healthy controls.5 In patients with VBD, immunohistochemical analyses of tissue samples obtained from biopsy or therapeutic vestibulectomy reveal an elevation in neuronal markers, including protein gene product (PGP), alongside an overexpression of nociceptive receptors such as the vanilloid receptor VR1 (TRPV1).6,7 Neuroinflammation is a crucial factor in VBD, mostly instigated by mast cell activation. Mast cells, when stimulated by factors like infections or hormonal fluctuations, secrete histamine, cytokines, and nerve growth factor (NGF), which enhance the sensitivity of adjacent nerve endings and facilitate neuron sprouting.8,9 Peripheral nerves and mast cells can create a detrimental cycle of reciprocal activation via the release of neuropeptides, so sustaining an augmented inflammatory condition and resulting in peripheral sensitization and a progression from acute to neuropathic pain.8,9 Enhanced innervation correlates with heightened sensitivity in women with VBD, as evidenced by reduced vestibular sensory current perception thresholds (CPT) at vestibular locations relative to control women.10 Patients with vestibular pain disorder frequently respond to localized discomfort by tensing and contracting the pelvic levator muscles, resulting in challenging and painful vaginal penetration.11 Indeed, a significant proportion of individuals with VBD have dysfunction of the pelvic floor muscles, characterized by hyperactivity, elevated resting pelvic floor tone, impaired muscular control, and the presence of myofascial trigger points.12 The pathogenesis of VBD is multifaceted, necessitating healthcare providers to customize treatment regimens for each patient; however, local neuropathic pain mechanisms are believed to significantly contribute to the disease's progression. Treating vulvodynia is challenging due to its complexity, necessitating that existing treatment approaches be tailored to the many different aspects of the condition. At present, there are no defined protocols for the management of vulvodynia, and treatment modalities are diverse, including topical and oral pharmacotherapies (eg, tricyclic antidepressants), self-care interventions, physiotherapeutic approaches (eg, pelvic floor rehabilitation), and psychotherapeutic support.13 Targeted therapy of topical compounded medications in individuals with VBD can be justified by identifying the condition as a localized neuropathic pain (LNP) syndrome.14 LNP is a form of neuropathic pain distinguished by a persistent and localized region of intense pain accompanied by atypical sensory manifestations and/or involuntary symptoms (eg, allodynia and/or hyperalgesia) typical of neuropathic pain, experienced at a superficial level.15 In the absence of substantial evidence, various topical treatments were employed in clinical practice for patients with VBD and LNP, including anesthetics (lidocaine, capsaicin), antiepileptics (gabapentin), muscle relaxants (baclofen, diazepam), antidepressants (amitriptyline), and additional analgesics (cannabidiol).16, 17, 18, 19 Topical medications in VBD can exert localized effects on peripheral systems implicated in neuropathic pain, inhibiting peripheral sensitization and thereby reducing or eliminating the manifestations of central sensitization in patients with VBD. Moreover, topical therapies have the advantage of diminished systemic adverse effects due to negligible systemic absorption, minimal drug interactions, enhanced patient adherence, and direct access to the target site and underlying pain mechanism. Resiniferatoxin (RTX) is an extremely strong derivative of capsaicin that functions as a selective agonist of TRPV1, a nonselective cation channel found on nociceptive neurons.20 RTX binding to TRPV1 induces a pronounced and prolonged calcium influx in the cell, and the increased influx of calcium results in functional desensitization of nociceptive nerve terminals.21 Consequently, the neuron forfeits its capacity to convey pain signals. Consequently, RTX generates a prolonged analgesic effect by specifically targeting and inhibiting TRPV1-expressing nociceptive fibers, while sparing other sensory and motor neurons, so positioning it as a viable therapeutic drug for the management of neuropathic and inflammatory pain.20,21 The aim of this study was to evaluate the efficacy and safety of treatment in patients with VBD. The primary focus was on improving provoked burning, pain, and dyspareunia. Secondarily, the study aimed to objectively assess changes in the sensitivity of vestibular nerve endings following treatment. Materials and methods Study design From March 2025 to June 2025, we evaluated all women referred to our Lower Genital Tract Disease Unit for vulvar pain therapy to determine their eligibility for enrollment. All patients underwent a standardized history and physical examination, and women diagnosed with VBD were invited to participate in the study. This research was designed as a prospective, observational pilot trial, and the protocol received approval from the local Institutional Review Board. All participants provided written informed consent prior to enrollment and participation in any study-related procedures. Participants Eligible participants had to be a minimum of 18 years old and premenopausal, characterized by the absence of menstruation for fewer than 12 consecutive months, and pain must be confined to the vulvar vestibule and manifest during vaginal intercourse as well as during activities that exert pressure on the vestibule, such as tampon insertion, wearing tight clothing, cycling, or horseback riding. Furthermore, participants were required to possess a history of VBD for a minimum of 3 months, with the diagnosis validated by an experienced gynecologist utilizing a standardized gynecological examination methodology. Participants were excluded from the study if they met any of the following criteria: women currently using or who had used topical vulvar or vaginal medications within 30 days prior to enrollment were excluded. Additionally, women undergoing or who had undergone pelvic floor rehabilitation within the previous 2 months were ineligible. Furthermore, women with concurrent vulvar dermatoses or other vulvar conditions were excluded from participation. Outcomes Clinical results were evaluated through a combination of patient-reported metrics and objective clinical and neurophysiological assessments. Subjective pain intensity was assessed using a 0 to 10 Visual Analog Scale (VAS) to evaluate vulvar burning/pain and dyspareunia. Participants were instructed to evaluate their average pain intensity, with elevated ratings signifying increased pain severity. Vestibular sensitivity was evaluated by the vestibular cotton swab test. A little cotton-tipped applicator was gently rolled across the vestibular mucosa at the 1, 3, 5, 6, 7, 9, and 11 o’clock positions. Patients at each location were instructed to indicate pain level on a discrete visual analog scale from 1 (no pain) to 10 (maximum pain). The average of the results acquired from all examined sites was computed and utilized for analysis. The tone of the pelvic floor muscles was assessed through a clinical examination of the levator ani muscle complex conducted by a qualified clinician. Hypertonicity was measured using an empirical 4-point scale: grade 0 indicated no hypertonicity, grade 1 denoted mild hypertonicity, grade 2 represented moderate hypertonicity, and grade 3 signified severe hypertonicity. A neurophysiological evaluation of vestibular sensory function was conducted via current perception threshold (CPT) testing, a recognized technique for measuring the sensitivity of peripheral nerve fibers. CPT values were assessed utilizing the Neurometer CPT/C electrodiagnostic neurostimulator (Neurotron, Inc.), which administers constant alternating sinusoidal waveform electrical stimuli at 3 frequencies: 2000 Hz, targeting large myelinated Aβ fibers; 250 Hz, targeting Aδ fibers; and 5 Hz, targeting unmyelinated C fibers.10 The intensity of the stimulus varied from 0.001 to 9.99 mA. CPT measurements of the vulvar vestibule were acquired utilizing a G-trode vaginal/rectal electrode (Neurotron, Inc.), with threshold values documented in milliamperes (1 unit=0.01 mA). Participants who fulfilled the inclusion and exclusion criteria were enrolled and administered a dispenser device with RTX 10 mcg/ml cream. The topical medication will be administered via the Topi-CLICK dispenser. Topi-CLICK facilitates precise dosage measurement and application of topical drugs to the targeted location, hence reducing the likelihood of incorrect dosing and contamination while enhancing compliance and therapeutic effects. Each vestibular dose comprises 1 click of the Topi-CLICK dispenser, with each click representing a 1/4 rotation of the dispenser's base, delivering a precise dosage of 2.5 micrograms of the medication. Patients will be instructed to apply the cream to the vulvar vestibule once daily for 4 weeks before to bedtime. Baseline characteristics of the sample, including demographic features and clinical history, were summarized using standard descriptive statistics. Continuous variables were expressed as median and interquartile range (IQR), and categorical variables as absolute and relative frequencies (percentages). Spontaneous and provoked vulvar burning/pain, dyspareunia, and cotton swab test responses were measured using the visual analogue scale (VAS, 0–10 points) and reported at baseline and 1-month follow-up as median (IQR) values. Other quantitative parameters, including vestibular current perception thresholds (CPT) at different frequencies (2000 Hz, 250 Hz, and 5 Hz), were also summarized as median (IQR) values. Patients were further categorized according to the clinical evaluation of hypertonus of the levator ani complex at baseline and after 1-month. Statistical analysis Efficacy of RXT treatment was evaluated by comparing baseline and 1-month follow-up VAS scores, and vestibular CPT values using the Wilcoxon signed-rank test for paired data. Levator ani hypertonicity, analyzed as a binary variable, was compared with the McNemar test. Continuous variables were assessed for normality using the Shapiro–Wilk test. Normally distributed variables are presented as mean±standard deviation (SD), whereas non-normally distributed variables are presented as median and interquartile range (IQR). Categorical variables are reported as frequencies and percentages. Participants lost to follow-up were documented, and analyses were conducted on the available paired data. A 2-tailed P-value <.05 was considered statistically significant. All analyses were performed with SAS, version 9.4, and R software, version 4.2. Results Twenty-four patients were included, with a median age at the first visit of 31 years (IQR: 25–36); the youngest was 20 years old and the oldest 38 years old. All of them were diagnosed with VBD, with a median disease duration of 66 months (IQR: 36–96), ranging from 7 months to 18 years. Table 1 reports selected demographic, lifestyle, and clinical characteristics of the patients, including age and BMI, smoking habits, age at menarche, menstrual cycle regularity, menopausal status, past and current contraceptive use, previous pregnancies, and the presence of recurrent urinary or vaginal infections. Table 2 lists the previous treatments used by patients, with 83.3% having received transcutaneous electrical nerve stimulation, 75.0% vaginal diazepam, and 70.8% oral amitriptyline . Spontaneous and provoked pain/burning were reported, with median VAS scores of 4.0 (IQR: 0.0–7.0) and 7.0 (IQR: 5.5–8.5), respectively. Dyspareunia was prevalent, with a median VAS score of 9.5 (IQR: 8.0–10.0), while the swab test elicited a median score of 8.0 (IQR: 8.0–10.0). Clinical evaluation of the levator ani revealed hypertonicity in 62.5% of participants, categorized as mild in 41.7%, moderate in 8.3%, and severe in 12.5%. Vestibular CPT evaluation showed median thresholds of 35.0 (IQR: 25.0–65.0) at 5 Hz, 105.0 (IQR: 65.0–142.5) at 250 Hz and 257.5 (IQR: 202.5–300.0) at 2000 Hz. Table 1Baseline characteristic of the sampleTable 1 dummy alt textAge31 (25–36)BMI19.9 (19.1–22.6)Smoking habit No18 (75.0) Yes6 (25.0)Age at menarche12 (11–13)Menstrual cyclesa Regular16 (69.6) Irregular (<25 d)2 (8.7) Irregular (>35 d)1 (4.4) Amenorrhea for OC use2 (8.7) Menopausal status2 (8.7)Contraceptive—in the pasta No8 (36.4) Yes14 (43.6)Contraceptives—current use No13 (54.2) Yes11 (45.8)Previous pregnanciesa No21 (91.3) Yes2 (8.7)Recurrent UTI No15 (62.5) Yes9 (37.5)Recurrent vaginal infections No12 (50.0) Yes12 (50.0)Continuous data are expressed as median (interquartile range) and categorical data are expressed as absolute numbers (percentages).BMI, body mass index; OC, oral contraceptive; UTI, urinary tract infections.aThe sum does not reach the total due to missing values.Murina. Topical resiniferatoxin for vestibulodynia. Am J Obstet Gynecol 2026. Baseline characteristic of the sample Continuous data are expressed as median (interquartile range) and categorical data are expressed as absolute numbers (percentages). BMI, body mass index; OC, oral contraceptive; UTI, urinary tract infections. The sum does not reach the total due to missing values. Murina. Topical resiniferatoxin for vestibulodynia. Am J Obstet Gynecol 2026. Table 2Previous treatmentsTable 2 dummy alt textPrevious treatmentN tot=24, n (%)TENS20 (83.3)Diazepam vaginal18 (75.0)Amitriptyline17 (70.8)Electroporation11 (45.8)Topical formulation E+T9 (37.5)Pelvic floor rehabilitation7 (29.2)Pregabalin4 (16.7)Clonazepam3 (12.5)Botulinum toxin3 (12.5)Tramadol2 (8.3)Duloxetin2 (8.3)CBD2 (8.3)Laser1 (4.2)Ozone therapy1 (4.2)Gabapentin1 (4.2)Radiofrequency1 (4.2)Vaginal dilators1 (4.2)One subject could undergo more the 1 previous treatment.CBD, cannabidiol; E-T, estriol-testosteron; TENS, transcutaneous electrical nerve stimulation.Murina. Topical resiniferatoxin for vestibulodynia. Am J Obstet Gynecol 2026. Previous treatments One subject could undergo more the 1 previous treatment. CBD, cannabidiol; E-T, estriol-testosteron; TENS, transcutaneous electrical nerve stimulation. Murina. Topical resiniferatoxin for vestibulodynia. Am J Obstet Gynecol 2026. Almost all patients (21/24, 87.5%) reported a tolerable burning sensation upon application of the cream formulation of RTX. These uncomfortable sensations usually improved or disappeared after the first treatment days. Five participants (20.8%) discontinued the study due to these side effects, indicating overall good tolerability, with only a minority of participants experiencing local reactions severe enough to cause discontinuation. Efficacy of RXT treatment was evaluated by comparing baseline and 1-month follow-up VAS scores only on the subset of participants with complete follow-up data. Figure 1 and Table 3 shows VAS scores related to spontaneous and provoked pain/burning, dyspareunia, and swab test. All symptoms improved at the 1-month follow-up after treatment, with the greatest changes observed for provoked pain/burning and dyspareunia, which showed median reductions of 2.0 (P=.01) and 2.5 (P=.01) points, respectively. Figure 2 shows the change in the proportion of levator ani hypertonicity before and after treatment. Although the proportion of women experiencing hypertonicity decreased (47.4% vs 63.2% at baseline), this reduction did not reach statistical significance (P=.08). The percentage of women with severe hypertonicity remained unchanged at 5.3%, while those with mild hypertonicity decreased from 47.4% to 36.8%, and those with moderate hypertonicity decreased from 10.5% to 5.3%. Figure 3 and Table 1 shows CPT levels, with improvements observed at 250 Hz and 5 Hz, but no significant change at 2000 Hz. Symptoms at baseline and at 1-month follow-up after treatment with resiniferatoxin Notes: Box represents the interquartile range (25th to 75th percentiles), with the median indicated by the line inside. Whiskers extend to 1.5× IQR, and outliers are plotted individually. *P-values calculated using the Wilcoxon signed-rank test for paired data. Murina. Topical resiniferatoxin for vestibulodynia. Am J Obstet Gynecol 2026. Table 3Symptoms and clinical evaluation at baseline and at 1-month follow-up after treatment with resiniferatoxinTable 3 dummy alt textBaseline1-mo follow-upSymptoms (VAS scores)Spontaneous pain/burning4.0 (0.0–7.0)2.0 (0.0–6.0)Provoked pain/burning7.0 (5.5–8.5)5.0 (3.0–7.0)Dyspareunia9.5 (8.0–10.0)7.0 (5.0–8.0)Swab test8.0 (8.0–10.0)6.9 (5.0–10.0)Clinical evaluationHypertonus of the levator ani No hypertonicity9 (37.5%)10 (52.6%) Mild hypertonicity10 (41.7%)7 (36.8%) Moderate hypertonicity2 (8.3%)1 (5.3%) Severe hypertonicity3 (12.5%)1 (5.3%)VeTH score4.0 (3.0–5.0)3.0 (2.0–4.0)Vestibular CPT evaluation5 Hz35.0 (25.0–65.0)60.0 (35.0–95.0)250 Hz105.0 (65.0–142.5)180.0 (80.0–220.0)2000 Hz257.5 (202.5–300.0)330.0 (250.0–380.0)Abbreviations: CPT, current perception threshold; VAS, visual analogue scale; VeTH, vestibular trophism health. VAS, VeTH scores, and CPT thresholds are expressed as the median and interquartile range.Murina. Topical resiniferatoxin for vestibulodynia. Am J Obstet Gynecol 2026. Symptoms and clinical evaluation at baseline and at 1-month follow-up after treatment with resiniferatoxin Abbreviations: CPT, current perception threshold; VAS, visual analogue scale; VeTH, vestibular trophism health. VAS, VeTH scores, and CPT thresholds are expressed as the median and interquartile range. Murina. Topical resiniferatoxin for vestibulodynia. Am J Obstet Gynecol 2026. Hypertonicity of levator ani at baseline and at 1-month follow-up after treatment with resiniferatoxin Notes: P-value calculated using the McNemar test. Murina. Topical resiniferatoxin for vestibulodynia. Am J Obstet Gynecol 2026. Current perception threshold (CPT) levels at baseline and at 1-month follow-up after treatment with resiniferatoxin Notes: Box represents the interquartile range (25th to 75th percentiles), with the median indicated by the line inside. Whiskers extend to 1.5× IQR, and outliers are plotted individually. *P-values calculated using the Wilcoxon signed-rank test for paired data. Murina. Topical resiniferatoxin for vestibulodynia. Am J Obstet Gynecol 2026. Discussion In this observational pilot study of women with VBD treated with topical RTX, we observed a significant improvement in values regarding vulvar pain and dyspareunia, in addition to an objective increase of the vestibular pain thresholds at follow-up, as compared to before the treatment started. To our knowledge, this is the first prospective clinical study reporting outcomes of topical RTX treatment in women with VBD together with objective vestibular neurophysiological assessment using CPT measurements. Recently, RTX was also identified among emerging therapeutic options for provoked VBD during the Vulvodynia Summit consensus initiative, highlighting the growing interest in TRPV1-targeted therapies in this field.22 Why might RTX influence the pathophysiological mechanisms associated with VBD? RTX, derived from the Euphorbia resinifera plant, is the most potent endogenous and synthetic agonist for TRPV1.23 RTX causes extremely prolonged channel opening and calcium influx, resulting in a highly selective temporary conduction defect in TRPV1-positive nerve fibers, while sparing large proprioceptive axons and sensations of light touch, cold, and pressure because these fibers do not significantly express TRPV1.24,25 Indeed, the recurrent administration of RTX results in the selective targeting and irreversible elimination of TRPV1-expressing Aδ and C-fiber neuronal cell bodies inside the dorsal root ganglia.24,25 The loss of these sensory neurons disrupts the transmission of nociceptive information from the body to second-order spinal cord neurons, which subsequently relay the information to the brain.24 There is substantial scientific evidence indicating a strong correlation between VBD and TRPV1 expression at both genetic and protein levels. TRPV1 seems to play a crucial role in mediating pain sensitization in this condition, influenced by factors such as neuroinflammation, gene polymorphisms, and neuroproliferation, all key features observed in patients with VBD.5,7,26 TRPV1-targeted therapies, like RTX, may explain our positive results, which are also confirmed by the improvement of CPT values related to changes in nerve fiber sensitivity. Our data indicated an increase in CPT levels, with significant improvements observed at 250 Hz and 5 Hz (approximately 58% for both), which target Aδ and C-fibers, respectively. In contrast, the improvement at 2000 Hz, which targets Aβ fibers, was lower and not statistically significant. The current findings, based on an objective parameter, underscore the role of RTX on TRPV1, which is predominantly expressed in unmyelinated C-fibers and myelinated Aδ-fibers.27 RTX is a capsaicin analogue that is about 1000 times more potent than capsaicin for the alleviation of neuropathic pain for its capacity to bind with nanomolar affinity to TRPV1.28 Topical capsaicin has been utilized in treating VBD, yielding encouraging results. However, compliance is often reduced due to considerable burning sensations after application and the necessity of prolonged application periods to sustain and consolidate the benefits obtained.29, 30, 31 In contrast to capsaicin, which induces a fast calcium influx via TRPV1, the current elicited by RTX is gradual and prolonged.26 This behavior may elucidate why RTX utilized in our investigation is significantly less irritating than capsaicin at the levels required for clinically effective desensitization, with a temporary burning sensation leading to treatment discontinuation in only 5 patients. Although RTX's primary action is not focused on altering pelvic musculature, we noted an intriguing reduction in hypertonicity, likely resulting from decreased pain perception. However, it is important to mention that about 80% of the patients either did not show muscle hypertonia or only exhibited mild cases. This element, viewed from a forward-looking perspective, may serve as an inclusion criterion for indicating either the standalone use of RTX or its application in multimodal therapy alongside pelvic floor rehabilitation for patients experiencing moderate to severe hypertonic dysfunction. Pain originating from a peripheral source, such as the VBD, is an ideal candidate for therapy with topical RTX at the generator area. This framework admits the presence of central sensitization, as evidenced in individuals with VBD, which is dynamically sustained by nociceptive input from areas of tissue injury.4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32 Moreover, inhibiting the peripheral generator might lead to the alleviation of the patient's pain despite the presence of central alterations, as observed in several animal models of neuropathic pain.33 This peripheral perspective serves as the primary conceptual premise for applying topical RTX in the treatment of VBD. Limitations of this study are its observational design, the small sample size treated with RTX, and the limited duration of follow-up. Despite these limitations, our findings indicate that conducting replications with larger samples in a placebo-controlled trial is necessary to confirm the validity of the current results and to understand their practical implications. In conclusion, the application of RTX improved both symptoms—specifically vulvar pain and dyspareunia—and nerve fiber oversensitivity, as indicated by changes in CPT values, in the patients included in this study. RTX appears to be a promising treatment option for women with VBD. However, further validation of its effectiveness is necessary through larger, placebo-controlled studies with extended follow-up periods. CRediT authorship contribution statement Filippo Murina: Writing – review & editing, Writing – original draft, Methodology, Investigation, Formal analysis, Data curation, Conceptualization. Cecilia Fochesato: Writing – original draft, Investigation, Data curation. Matteo Mantovani: Project administration, Methodology, Conceptualization. Matilde Slanzi: Validation, Investigation, Formal analysis, Data curation. Marianna Donini: Validation, Investigation, Formal analysis, Data curation. Nicla Toni: Project administration, Investigation, Data curation. Valeria Savasi: Writing – review & editing, Supervision, Methodology. Footnotes The authors report no conflict of interest. Ethics statement: Approved by the Institutional Review Board of V. Buzzi Hospital-Milan (Italy) (protocol code December, 2025, date of approval: January 21, 2025). References